View in EDS

Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemia.

Saved in:
Bibliographic Details
Title: Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemia.
Authors: Moore CG; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Chyong DI; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Daver N; MD Anderson Cancer Center, Houston, Texas, USA., Aubrey BJ; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Marx KR; MD Anderson Cancer Center, Houston, Texas, USA., Takahashi K; MD Anderson Cancer Center, Houston, Texas, USA., Abaza Y; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA., Smith CC; University of California San Francisco, San Francisco, California, USA., Amrein PC; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Hock H; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Hobbs G; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Narayan R; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Lee MH; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Moran JA; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Bergeron M; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Foster JE; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Perl AE; University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, USA., Levis MJ; Johns Hopkins Cancer Center, Baltimore, Maryland, USA., DiNardo CD; MD Anderson Cancer Center, Houston, Texas, USA., Brunner AM; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Fathi AT; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Source: British journal of haematology [Br J Haematol] 2026 Jul 12. Date of Electronic Publication: 2026 Jul 12.
Publication Type: Journal Article
Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42438311
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemia.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Moore+CG%22">Moore CG</searchLink>; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Chyong+DI%22">Chyong DI</searchLink>; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Daver+N%22">Daver N</searchLink>; MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Aubrey+BJ%22">Aubrey BJ</searchLink>; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Marx+KR%22">Marx KR</searchLink>; MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Takahashi+K%22">Takahashi K</searchLink>; MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Abaza+Y%22">Abaza Y</searchLink>; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Smith+CC%22">Smith CC</searchLink>; University of California San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Amrein+PC%22">Amrein PC</searchLink>; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Hock+H%22">Hock H</searchLink>; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Hobbs+G%22">Hobbs G</searchLink>; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Narayan+R%22">Narayan R</searchLink>; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Lee+MH%22">Lee MH</searchLink>; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Moran+JA%22">Moran JA</searchLink>; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Bergeron+M%22">Bergeron M</searchLink>; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Foster+JE%22">Foster JE</searchLink>; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Perl+AE%22">Perl AE</searchLink>; University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Levis+MJ%22">Levis MJ</searchLink>; Johns Hopkins Cancer Center, Baltimore, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22DiNardo+CD%22">DiNardo CD</searchLink>; MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Brunner+AM%22">Brunner AM</searchLink>; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Fathi+AT%22">Fathi AT</searchLink>; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220372544%22">British journal of haematology</searchLink> [Br J Haematol] 2026 Jul 12. <i>Date of Electronic Publication: </i>2026 Jul 12.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Blackwell%22">Wiley-Blackwell </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>0372544 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1365-2141 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200071048%22">00071048 </searchLink><i>NLM ISO Abbreviation: </i>Br J Haematol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42438311
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/bjh.70671
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemia.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Moore CG
      – PersonEntity:
          Name:
            NameFull: Chyong DI
      – PersonEntity:
          Name:
            NameFull: Daver N
      – PersonEntity:
          Name:
            NameFull: Aubrey BJ
      – PersonEntity:
          Name:
            NameFull: Marx KR
      – PersonEntity:
          Name:
            NameFull: Takahashi K
      – PersonEntity:
          Name:
            NameFull: Abaza Y
      – PersonEntity:
          Name:
            NameFull: Smith CC
      – PersonEntity:
          Name:
            NameFull: Amrein PC
      – PersonEntity:
          Name:
            NameFull: Hock H
      – PersonEntity:
          Name:
            NameFull: Hobbs G
      – PersonEntity:
          Name:
            NameFull: Narayan R
      – PersonEntity:
          Name:
            NameFull: Lee MH
      – PersonEntity:
          Name:
            NameFull: Moran JA
      – PersonEntity:
          Name:
            NameFull: Bergeron M
      – PersonEntity:
          Name:
            NameFull: Foster JE
      – PersonEntity:
          Name:
            NameFull: Perl AE
      – PersonEntity:
          Name:
            NameFull: Levis MJ
      – PersonEntity:
          Name:
            NameFull: DiNardo CD
      – PersonEntity:
          Name:
            NameFull: Brunner AM
      – PersonEntity:
          Name:
            NameFull: Fathi AT
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 12
              M: 07
              Text: 2026 Jul 12
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1365-2141
          Titles:
            – TitleFull: British journal of haematology
              Type: main
ResultId 1